Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.45 |
| ▸ | Q9HBH1 | 1/20 | 0.44 | |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.43 |
| ▸ | FURIN | P09958 | 1/20 | 0.42 |
| ▸ | CHRND | Q07001 | 5/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.42 |
| ▸ | CHRNG | P07510 | 1/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24390289 | 0.93 | SIRT1 (0.45) | SIRT1PDFSIRT2SIRT3SSTR3 | |
| SCHEMBL26033422 | 0.93 | SIRT1 (0.45) | SIRT1PDFSIRT2SIRT3SSTR3 | |
| SCHEMBL26017207 | 0.93 | MMP3 (0.43) | SIRT1PDFSIRT2SIRT3SSTR3 | |
| SCHEMBL24906651 | 0.93 | SIRT1 (0.45) | SIRT1PDFSIRT2SIRT3SSTR3 | |
| SCHEMBL26192867 | 0.93 | MMP3 (0.43) | SIRT1PDFSIRT2SIRT3SSTR3 | |
| SCHEMBL19915429 | 0.89 | SIRT1 (0.47) | SIRT1SIRT2SIRT3FURINCHRND | |
| SCHEMBL19687799 | 0.86 | SIRT2 (0.42) | SIRT1SIRT2SIRT3FURIN | |
| SCHEMBL19687798 | 0.86 | SIRT2 (0.42) | SIRT1SIRT2SIRT3FURIN | |
| SCHEMBL26029328 | 0.85 | FURIN (0.43) | SIRT1PDFSIRT2SIRT3SSTR3 | |
| SCHEMBL26017200 | 0.85 | MMP3 (0.43) | SIRT1PDFSIRT2SIRT3SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263899-A1 | FOLATE RECEPTOR TARGETED NANOPARTICLE DRUG CONJUGATES AND USES THEREOF | FOLR1, FOLR2, DHFR | SIRT1 2883/4885PDF 421/4885SIRT2 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.